These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
586 related items for PubMed ID: 29425203
1. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. Budigi Y, Ong EZ, Robinson LN, Ong LC, Rowley KJ, Winnett A, Tan HC, Hobbie S, Shriver Z, Babcock GJ, Alonso S, Ooi EE. PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203 [Abstract] [Full Text] [Related]
10. Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection. Xu M, Züst R, Toh YX, Pfaff JM, Kahle KM, Davidson E, Doranz BJ, Velumani S, Tukijan F, Wang CI, Fink K. J Virol; 2016 Dec 15; 90(24):11122-11131. PubMed ID: 27707930 [Abstract] [Full Text] [Related]
12. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. Ramasamy V, Arora U, Shukla R, Poddar A, Shanmugam RK, White LJ, Mattocks MM, Raut R, Perween A, Tyagi P, de Silva AM, Bhaumik SK, Kaja MK, Villinger F, Ahmed R, Johnston RE, Swaminathan S, Khanna N. PLoS Negl Trop Dis; 2018 Jan 15; 12(1):e0006191. PubMed ID: 29309412 [Abstract] [Full Text] [Related]
15. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE. J Virol; 2014 Nov 15; 88(21):12233-41. PubMed ID: 25100837 [Abstract] [Full Text] [Related]
16. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E. mBio; 2017 Sep 19; 8(5):. PubMed ID: 28928210 [Abstract] [Full Text] [Related]
18. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK. J Virol; 2013 Dec 19; 87(23):12562-75. PubMed ID: 24027331 [Abstract] [Full Text] [Related]
19. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Ramadhany R, Hirai I, Sasaki T, Ono K, Ramasoota P, Ikuta K, Kurosu T. Antiviral Res; 2015 Dec 19; 124():61-8. PubMed ID: 26522769 [Abstract] [Full Text] [Related]
20. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies. Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK. J Virol; 2015 Jul 19; 89(14):7348-62. PubMed ID: 25972550 [Abstract] [Full Text] [Related] Page: [Next] [New Search]